- Home
- RGF vs EDSA Comparison
RGF vs EDSA Comparison
Compare RGF & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGF
- EDSA
- Stock Information
- Founded
- RGF 2016
- EDSA 2015
- Country
- RGF United States
- EDSA Canada
- Employees
- RGF N/A
- EDSA N/A
- Industry
- RGF Packaged Foods
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- RGF Consumer Staples
- EDSA Health Care
- Exchange
- RGF Nasdaq
- EDSA Nasdaq
- Market Cap
- RGF 6.4M
- EDSA 7.1M
- IPO Year
- RGF 2021
- EDSA N/A
- Fundamental
- Price
- RGF $0.24
- EDSA $2.11
- Analyst Decision
- RGF Hold
- EDSA Strong Buy
- Analyst Count
- RGF 1
- EDSA 1
- Target Price
- RGF $0.50
- EDSA $21.00
- AVG Volume (30 Days)
- RGF 132.4K
- EDSA 49.6K
- Earning Date
- RGF 12-03-2024
- EDSA 12-13-2024
- Dividend Yield
- RGF N/A
- EDSA N/A
- EPS Growth
- RGF N/A
- EDSA N/A
- EPS
- RGF N/A
- EDSA N/A
- Revenue
- RGF $156,379,000.00
- EDSA N/A
- Revenue This Year
- RGF $23.67
- EDSA N/A
- Revenue Next Year
- RGF N/A
- EDSA N/A
- P/E Ratio
- RGF N/A
- EDSA N/A
- Revenue Growth
- RGF 18.88
- EDSA N/A
- 52 Week Low
- RGF $0.21
- EDSA $2.05
- 52 Week High
- RGF $2.10
- EDSA $6.46
- Technical
- Relative Strength Index (RSI)
- RGF 27.82
- EDSA 23.05
- Support Level
- RGF $0.24
- EDSA $2.09
- Resistance Level
- RGF $0.27
- EDSA $2.32
- Average True Range (ATR)
- RGF 0.02
- EDSA 0.23
- MACD
- RGF -0.00
- EDSA 0.00
- Stochastic Oscillator
- RGF 8.16
- EDSA 6.52
About RGF The Real Good Food Company Inc.
The Real Good Food Co Inc is a frozen food company that develops, markets, and manufactures foods high in protein, low in sugar, and gluten- and grain-free. The company produces breakfast sandwiches, entrees, and other products, primarily sold in the U.S. frozen food category. All of its revenue is derived from the United States.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.